Anavex Life Sciences
AVXL
57 hedge funds and large institutions have $23.8M invested in Anavex Life Sciences in 2018 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 15 increasing their positions, 15 reducing their positions, and 16 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 15
6% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 16
2% less funds holding
Funds holding: 58 → 57 (-1)
2.71% less ownership
Funds ownership: 23.07% → 20.36% (-2.7%)
16% less capital invested
Capital invested by funds: $28.4M → $23.8M (-$4.55M)
79% less call options, than puts
Call options by funds: $195K | Put options by funds: $926K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.87M |
| 2 |
Goldman Sachs
New York
|
+$791K |
| 3 |
ECM
Element Capital Management
New York
|
+$561K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$535K |
| 5 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
+$477K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.39M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.66M |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$944K |
| 4 |
TCIM
TIAA CREF Investment Management
New York
|
-$292K |
| 5 |
Bank of New York Mellon
New York
|
-$256K |
AVXL Hedge Fund Activity: Q2 2018 in Review
57 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Anavex Life Sciences (AVXL) for Q2 2018, worth a combined $23.8M — down 16% from $28.4M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of AVXL and 15 opened new positions — a net loss of 1 holder — while 15 trimmed existing stakes and 15 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $1.87M. The largest seller was BlackRock, cutting an estimated $4.39M.
- 57 institutional investors held Anavex Life Sciences (AVXL) as of Q2 2018, down from 58 in Q1 2018.
- Funds reported $23.8M of Anavex Life Sciences stock for Q2 2018, down 16% quarter-over-quarter.
- 15 funds opened new Anavex Life Sciences positions in Q2 2018 and 16 closed out, a net change of -1 holder.
- The largest Anavex Life Sciences buyer in Q2 2018 was Millennium Management, an estimated $1.87M added.
- The largest Anavex Life Sciences seller in Q2 2018 was BlackRock, an estimated $4.39M sold.
Based on aggregated 13F filings for Q2 2018.